Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Indaptus Therapeutics, Inc.

NASDAQ: INDP · Life Sciences · 4 alerts · CIK 1857044

Share price
$3.45Close, Nov 16
Market cap
$530M
Shares outstanding
153.6MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Indaptus Therapeutics, Inc. filings on SEC EDGAR ↗

4:31 PM ET 8-K
Financial Results

Indaptus Therapeutics Financial Results

Indaptus Therapeutics reported its Q3 2026 financial results, highlighting a cash and short-term investment position of approximately $30.6 million following a $24 million private placement. The company is shifting its strategic focus toward neurotechnology and neural-network-based devices for sleep-related conditions while significantly reducing R&D expenses by 82% year-over-year.

“Our strategic objective is to position Indaptus for its next phase of growth by actively pursuing innovative opportunities with significant long-term potential and expanding the Company’s strategic focus into promising areas of medical innovation. We believe the successful completion of our approximately $24.0 million private placement provides an important foundation to advance this vision, giving us the financial resources and strategic flexibility to explore new opportunities and build long-term shareholder value.”

Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board

“We are particularly excited about the opportunity to explore the potential of an innovative neurotechnology- and neural-network-based device for certain sleep-related conditions. We believe this area represents an intriguing opportunity to investigate novel approaches to addressing unmet needs in sleep-related health. Through early-stage research and preclinical evaluation, we hope to further assess its scientific potential and explore a possible development pathway toward a future FDA submission.”

Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board
8:31 AM ET 10-Q
Financial Results

Indaptus Therapeutics Q3 2026 Results: Net Loss of $1.05M, Loss Narrows

Indaptus Therapeutics reported a net loss of $5.38 million for the nine months ended September 30, 2026, a significant reduction from the $12.74 million loss in the prior year period. The company's cash position strengthened to $26.60 million following significant common stock issuances and preferred stock conversions, while operating expenses decreased across both R&D and G&A categories.

Key figure
Net loss $1.05M
4:38 PM ET 8-K
Capital Raise

Indaptus Therapeutics Capital Raise of $24M

Indaptus Therapeutics completed a private placement of 20,338,974 shares of common stock for aggregate gross proceeds of approximately $24.0 million. The closing follows a previously announced stock purchase agreement dated September 8, 2026, and a subsequent extension of the outside closing date to October 16, 2026.

Value
$24M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.